Prof. Dr. Lucas Villas BΓ΄as Hoelz | Medicinal Chemistry | Best Researcher Award
Prof. Dr. Lucas Villas BΓ΄as Hoelz, Instituto Federal do Rio de Janeiro, IFRJ, Brazil.
Professional Profile
π Early Academic Pursuits
Prof. Dr. Lucas Villas Boas Hoelz embarked on his academic journey with a strong foundation in Pharmacy at the Universidade Federal do Rio de Janeiro (UFRJ), graduating in 2004. He later pursued a Master’s degree (2007) and a Doctorate (2011) in Chemistry at UFRJ. His doctoral research focused on the theoretical study of beta1-adrenoceptor activation mediated by R-noradrenaline, under the supervision of Ricardo Bicca de Alencastro. He further expanded his expertise through postdoctoral studies at UFRJ and the Programa de PΓ³s-Graduação em CiΓͺncias Aplicadas a Produtos para a SaΓΊde (PPG-CAPS), solidifying his expertise in medicinal chemistry and computational modeling.
πΌ Professional Endeavors
Dr. Hoelz has held multiple roles in academia and research. He currently serves as a Professor at the Instituto Federal do Rio de Janeiro (IFRJ) and is the coordinator of the Computational Medicinal Chemistry Laboratory (LCQM) at Campus Pinheiral-IFRJ. His professional trajectory includes positions as a temporary professor, tutor, and research fellow at various institutions. He has also contributed to postgraduate education as a permanent faculty member and graduate program mentor.
π¬ Contributions and Research Focus On Medicinal Chemistry
Dr. Hoelz specializes in Medicinal Chemistry, Organic Synthesis, Molecular Modeling, and Molecular Dynamics of Biological Systems. His research primarily addresses COVID-19, neglected diseases, AIDS, and cancer, focusing on the computational and experimental design of bioactive compounds. His work integrates comparative protein modeling, protein dynamics, and synthesis of new therapeutic agents, significantly advancing drug discovery efforts.
π Impact and Influence
Through his research and academic contributions, Dr. Hoelz has played a key role in developing novel drug candidates and therapeutic strategies. His investigations into molecular interactions and drug mechanisms have informed the development of treatment methodologies for major global health concerns. His work has influenced both the scientific community and pharmaceutical industry, fostering innovation in medicinal chemistry.
π Academic Citations
Dr. Hoelz’s research has been widely recognized and cited in various peer-reviewed journals and academic conferences. His studies on molecular modeling, organic synthesis, and drug discovery have garnered substantial academic interest, reflecting the impact and relevance of his work in the field of medicinal chemistry.
π Awards and Honors
Dr. Hoelz has received multiple scholarships and fellowships from prestigious organizations, including the Coordination for the Improvement of Higher Education Personnel (CAPES) and the National Council for Scientific and Technological Development (CNPq). His work has been recognized for its contributions to medicinal chemistry, with awards highlighting his excellence in research and teaching.
π Legacy and Future Contributions
With a distinguished career in computational medicinal chemistry, Dr. Hoelz continues to expand his contributions by mentoring the next generation of researchers, publishing influential studies, and advancing computational approaches in drug design. His leadership at the LCQM ensures ongoing research in biomedical innovation, shaping the future of medicinal chemistry and molecular dynamics.
Publications Top Notes
π¦ Antiviral Research
1οΈβ£ The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
π Scientific Reports 7 (1), 40920
π
2017 | π’ 250 citations
2οΈβ£ Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo
π PLoS Neglected Tropical Diseases 13 (1), e0007072
π
2019 | π’ 113 citations
3οΈβ£ In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2
π Journal of Antimicrobial Chemotherapy 76 (7), 1874-1885
π
2021 | π’ 110 citations
4οΈβ£ Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication
π Antimicrobial Agents and Chemotherapy 63 (2), 10.1128/aac.01389-18
π
2019 | π’ 103 citations
π¦ Malaria & Parasitic Disease Research
5οΈβ£ Evaluation of 7-arylaminopyrazolo [1, 5-a] pyrimidines as anti-Plasmodium falciparum inhibitors
π European Journal of Medicinal Chemistry 126, 72-83
π
2017 | π’ 77 citations
6οΈβ£ Plasmodium Falciparum Dihydroorotate Dehydrogenase: A Drug Target against Malaria
π Future Medicinal Chemistry 10 (15), 1853-1874
π
2018 | π’ 55 citations
7οΈβ£ Comparative study between anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine, and quinoline derivatives
π European Journal of Medicinal Chemistry 209, 112941
π
2021 | π’ 34 citations
π§ͺ Medicinal & Pharmaceutical Chemistry
8οΈβ£ Pyrroles as privileged scaffolds in the search for new potential HIV inhibitors
π Pharmaceuticals 14 (9), 893
π
2021 | π’ 54 citations
9οΈβ£ Receptor-dependent (RD) 3D-QSAR approach of benzylpiperidine inhibitors of human acetylcholinesterase
π European Journal of Medicinal Chemistry 46 (1), 39-51
π
2011 | π’ 32 citations
π New pyrazolopyrimidine derivatives as Leishmania amazonensis arginase inhibitors
π Bioorganic & Medicinal Chemistry 27 (14), 3061-3069
π
2019 | π’ 22 citations
π¦ Other Infectious Disease Research
1οΈβ£1οΈβ£ Structural and Functional Analysis of a Platelet-Activating Lysophosphatidylcholine of Trypanosoma cruzi
π PLoS Neglected Tropical Diseases 8 (8), e3077
π
2014 | π’ 36 citations
1οΈβ£2οΈβ£ New 1,2,3βtriazoleβbased analogues of benznidazole for use against Trypanosoma cruzi infection
π Medicinal Chemistry Research
π
Year N/A | π’ Citations N/A
π¬ Computational & Molecular Research
1οΈβ£3οΈβ£ Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent
π Journal of Biomolecular Structure and Dynamics 34 (9), 1969-1978
π
2016 | π’ 20 citations
1οΈβ£4οΈβ£ P2X7 receptor inhibition by 2-amino-3-aryl-1,4-naphthoquinones
π Bioorganic Chemistry 104, 104278
π
2020 | π’ 18 citations
π₯ Cancer & Leukemia Research
1οΈβ£5οΈβ£ Imatinib derivatives as inhibitors of K562 cells in chronic myeloid leukemia
π Medicinal Chemistry Research 26, 2929-2941
π
2017 | π’ 17 citations
ποΈ Green Chemistry & Synthesis
1οΈβ£6οΈβ£ Solvent Free, Microwave Assisted Conversion of Aldehydes into Nitriles and Oximes
π Molecules 15 (1), 94-99
π
2009 | π’ 17 citations